Clinical Trial
Fact Sheet

JORDAN'S GUARDIAN ANGELS

WHAT:
A randomized, double-blind placebo-controlled study of Zatolmilast (BPN14770) in individuals with PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome).

WHO:
Ages 9 - 45
with PPP2R5D

WHERE:
-Boston: Boston Children's Hospital
-Seattle: Seattle Children's Hospital
-Chicago: Rush University Medical Center

Guidelines

- English as first and primary language
- Anti-epileptic medications must be at a stable dose and dosing regimen for 12 weeks prior to Screening.
- Current treatment with no more than 3 prescribed psychotropic medications. Anti-epileptic medications are permitted and are not counted as psychotropic medications if they are used for treatment of seizures.
- Permitted concomitant psychotropic medications must be at a stable dose and dosing regimen for at least 2 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication. Every effort should be made to keep dosing stable throughout the study.
- Can swallow capsules or soft food.

Study Commitment

- The study is 12 months in length.
- There will be four to five face to face visits over 24 weeks during the double blinded study.
- There will also be three face to face visits over 24 weeks during the open label treatment.
- Each visit will take up to a full day.

Exclusion Criteria

- Body weight less than 25 kg.
- BMI less than 18 or greater than 36.
- History of some kinds of serious kidney or liver diseases.

Interested in Participating?

Please reach out to Joanne Carroll CPNP for more information at **joanne.carroll@childrens.harvard.edu**

**Please note, by emailing this does not mean that you are enrolled in the clinical trial. This is simply to gather information on who might be interested in participating.

Please visit the JGA Research Resources page (https://jordansguardianangels.org/research-resources/) for the clinical trial's tentative assessment schedule .